GS-441524 for FIP: 92% Success Rate, Evidence Explained
Before 2019, Feline Infectious Peritonitis was considered almost universally fatal. Corticosteroids could slow progression temporarily. Supportive care could buy days or weeks. Nothing could stop the disease. The Pedersen et al. 2019 UC Davis trial (J Feline Med Surg) changed that permanently.
GS-441524 antiviral treatment achieves a 92% success rate across all forms of FIP when administered at the correct dose for the full 84-day protocol. That number comes from the most rigorous clinical study of FIP treatment ever conducted — and it has been reproduced in real-world treatment programs across multiple countries since publication.
This article explains what the evidence actually shows, how GS-441524 works, what the 92% figure means in practice, and which factors determine whether a cat achieves full remission.
The Evidence: What the UC Davis Trial Found
The Pedersen et al. 2019 trial enrolled 31 cats with confirmed FIP across multiple forms — wet, dry, neurological, and ocular. Cats received GS-441524 by subcutaneous injection at doses ranging from 4 to 10 mg/kg daily depending on FIP form, for a minimum of 12 weeks (84 days).
Results:
- 25 of 26 cats that completed the full protocol achieved sustained remission — a 96% completion rate among cats that finished treatment
- Overall success rate across all enrolled cats: approximately 92%
- Cats in remission were followed for a minimum of 12 weeks post-treatment; none relapsed during the observation period
- Cats that relapsed during treatment were successfully retreated at higher doses
- The drug was well tolerated across all forms and age groups, including kittens
This was not a small pilot study. It was a prospective, monitored clinical trial with confirmed FIP diagnoses, standardised dosing, and structured follow-up. The 92% figure is not marketing language — it is a peer-reviewed clinical outcome published in the Journal of Feline Medicine and Surgery.
The earlier Pedersen et al. 2018 study (Vet Microbiology) confirmed GS-441524’s mechanism and efficacy in tissue culture and experimental infection models, establishing the pharmacological foundation for the 2019 trial.
How GS-441524 Works
GS-441524 is a nucleoside analogue — a synthetic compound that mimics the building blocks of viral RNA. When the FIP virus attempts to replicate inside infected macrophages, it incorporates GS-441524 into its RNA strand. This terminates the replication process: the RNA strand cannot extend further, and the virus cannot produce functional copies of itself.
This mechanism — RNA chain termination — is highly specific to the viral RNA polymerase. It does not affect the cat’s own cellular machinery at therapeutic doses, which is why GS-441524 has a favourable safety profile.
As viral replication is suppressed, the inflammatory cascade that causes FIP’s damage begins to resolve. The fever breaks because the inflammatory trigger is being removed. The fluid reabsorbs because the vasculitis driving it is resolving. The cat starts eating because the systemic inflammation causing nausea is reducing. The drug does not destroy the virus directly — it stops it from replicating, and the immune system does the rest.
This is why the full 84-day protocol is essential. GS-441524 suppresses replication; it does not eliminate the virus instantly. Stopping early leaves residual viral replication occurring under sub-therapeutic conditions — the highest-risk scenario for relapse.
Efficacy Across All Four Forms of FIP
GS-441524 is effective across all four forms of FIP, but the required dose differs by form:
| FIP Form | Daily Injectable Dose | Product | Notes |
|---|---|---|---|
| Wet (Effusive) | 6 mg/kg | GS-441524 20 mg/ml | Fastest visible response — fluid begins reabsorbing within days |
| Dry (Non-effusive) | 8 mg/kg | GS-441524 20 mg/ml | Slower clinical response; blood work is the primary progress indicator |
| Ocular | 10 mg/kg | GS-441524 30 mg/ml | Higher dose required for therapeutic levels in ocular tissue |
| Neurological | 10 mg/kg | GS-441524 30 mg/ml | Higher dose required for CNS penetration; injectable strongly preferred |
Dosing follows Pedersen et al., UC Davis (PMC6435921). Your veterinarian confirms form and weight before the first injection.
The 2019 trial included cats with neurological FIP — historically the most difficult form to treat — and documented remission in these cases at 10 mg/kg. Neurological recovery is often gradual, continuing throughout the 84-day protocol and the observation period, but it is achievable. Read our guide to neurological FIP for more detail.
What Determines Whether a Cat Achieves Remission
The 92% success rate is achievable — but it is not automatic. The cats in the 2019 trial that did not achieve remission were predominantly those where treatment was started late, where the dose was insufficient for the FIP form, or where the full protocol was not completed. The factors that determine outcome are well understood:
How early treatment starts. The single most important variable. Every day without treatment allows the virus to replicate further and damage to accumulate. Neural tissue damaged by neurological FIP does not fully regenerate. Organ function compromised by advanced wet FIP recovers more slowly. The ABCD FIP guidelines identify early treatment as the most significant modifiable factor in FIP outcomes. Read our guide on why delaying FIP treatment is fatal.
Correct dosing. Under-dosing is the most common cause of treatment failure. The dose must be calculated precisely based on the cat’s current body weight and confirmed FIP form. A cat that gains weight during treatment needs a dose recalculation — particularly important in kittens, who grow significantly during the 84-day protocol.
Reliable drug delivery. Injectable GS-441524 produces consistent, predictable drug levels unaffected by gastrointestinal status. Oral capsules depend on absorption that can be compromised by vomiting, diarrhoea, or reduced gastric motility — all common in FIP cats, particularly in the early weeks of treatment. For neurological and ocular FIP, injectable is strongly preferred throughout. Read our injectable vs oral guide.
Completing the full 84-day protocol. Stopping early because the cat appears well is the most common cause of relapse. Clinical improvement is not viral clearance. The full 84 days is required. Read our FIP relapse guide.
Blood work monitoring at days 30, 60, and 84. Blood work confirms whether the albumin-to-globulin (A:G) ratio and other markers are improving as expected. A cat not responding as expected at day 30 needs dose review before day 60. Read our complete blood work guide.
What Happens After the 84-Day Protocol
After completing the 84-day protocol, a 12-week observation period follows with no GS-441524 administered. The immune system, now free of active viral replication, completes the clearance process. Blood work is checked at weeks 4, 8, and 12 of the observation period.
Cats that complete both phases without symptom recurrence are considered in full remission. In the 2019 trial, cats in remission were followed for a minimum of 12 weeks post-treatment with no relapses. Real-world follow-up data from treated cats confirms that full remission is durable — cats in remission go on to live normal, healthy lifespans.
Relapse after completing the full protocol and observation period is uncommon. When it does occur, retreatment with GS-441524 at an adjusted dose is effective in most cases. Read our FIP survival and treatment outlook guide for what full remission means long-term.
GS-441524 Safety Profile
GS-441524 is well tolerated at therapeutic doses across all age groups, including kittens. The most common side effects are local injection site reactions — mild swelling, firmness, or discomfort at the injection site — which are manageable with correct technique, site rotation, and room-temperature solution.
Systemic side effects are uncommon. Mild, transient increases in liver enzymes have been observed in some cats during treatment but typically resolve without intervention. Kidney function should be monitored in cats with pre-existing renal disease.
For a full guide to side effects, what is normal, and what warrants veterinary attention, read our GS-441524 side effects guide.
Frequently Asked Questions
What is the success rate of GS-441524 for FIP?
92%, documented by the Pedersen et al. 2019 UC Davis trial (J Feline Med Surg) when administered at the correct dose for the full 84-day protocol. This figure has been reproduced in real-world treatment programs across multiple countries since publication.
Does GS-441524 work for all forms of FIP?
Yes — wet, dry, ocular, and neurological FIP all respond to GS-441524. The dose differs by form: 6 mg/kg for wet FIP, 8 mg/kg for dry FIP, and 10 mg/kg for ocular and neurological FIP. The 2019 trial included all four forms.
How quickly does GS-441524 start working?
Most cats show the first signs of improvement — fever beginning to resolve, slight return of appetite — within 3 to 7 days of starting treatment at the correct dose. In wet FIP, abdominal fluid may begin to reduce visibly within the first week. Read our complete treatment timeline guide.
Can GS-441524 cure FIP permanently?
Cats that complete the full 84-day protocol and the 12-week observation period without symptom recurrence are considered in full remission. In the 2019 trial, no cats in remission relapsed during the observation period. Real-world follow-up data confirms that full remission is durable — cats in remission go on to live normal lifespans.
What happens if my cat relapses after GS-441524 treatment?
Relapse is most commonly caused by stopping treatment early or under-dosing. Retreatment with GS-441524 at an adjusted dose is effective in most relapse cases. Read our FIP relapse guide for the full picture.
Is GS-441524 safe for kittens?
Yes. GS-441524 is safe and effective for kittens at the correct weight-based dose. Because kittens grow during the 84-day protocol, body weight must be checked every 2 weeks and the dose adjusted accordingly. Read our complete guide to FIP in kittens.
GS-441524 is the most effective treatment for FIP ever documented — not because of marketing claims, but because of a peer-reviewed clinical trial conducted by the researcher who spent his career studying FIP. The 92% success rate is real, reproducible, and achievable for your cat when the protocol is executed correctly: right dose, injectable delivery, full 84 days, blood work at each interval.
For the complete step-by-step guide from diagnosis to completing the protocol, read our FIP action guide. The FIP CURE Plus team is available in English and Arabic at info@fipcureplus.com.
View the FIP CURE Plus GS-441524 injectable range →
FIP CURE Plus — transparent, evidence-based GS-441524 treatment for cats across the Gulf.